Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential-Reference-Cited by-同舟云学术

Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential

Author:

Tharian Leah R.¹^ORCID,Verma Shiv²³^ORCID,Gupta Sanjay²³⁴⁵⁶⁷^ORCID

Affiliation:

1. College of Arts and Sciences, Case Western Reserve University, Cleveland, OH 44016, USA

2. Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA

3. The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA

4. Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44016, USA

5. Department of Pathology, Case Western Reserve University, Cleveland, OH 44016, USA

6. Department of Nutrition, Case Western Reserve University, Cleveland, OH 44016, USA

7. Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA

Abstract

Prostate cancer, the most common cancer among males, has a mortality rate of approximately 29,000 deaths each year in the United States alone [...]

Funder

Department of Defense Grants

Publisher

MDPI AG

Link

Reference21 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

5. Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer;Boudadi;Clin. Med. Insights Oncol.,2016